Clinical analysis of 10 patients with de novo CD5 positive diffuse large B cell lymphoma.
10.7534/j.issn.1009-2137.2013.02.029
- Author:
Qian ZHANG
1
;
Hong-Yu ZHANG
;
Feng-Luan ZHONG
;
Wen-Li ZHANG
;
Lei XU
;
Jia FENG
;
Qing-Xiang MENG
Author Information
1. Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Aged, 80 and over;
Antibodies, Monoclonal, Murine-Derived;
therapeutic use;
CD5 Antigens;
metabolism;
Female;
Humans;
Lymphoma, Large B-Cell, Diffuse;
drug therapy;
metabolism;
pathology;
Male;
Middle Aged;
Neoplasm Staging;
Prognosis;
Retrospective Studies;
Rituximab;
Survival Rate;
Treatment Outcome
- From:
Journal of Experimental Hematology
2013;21(2):399-402
- CountryChina
- Language:Chinese
-
Abstract:
To explore the clinical characteristics, diagnosis, treatment outcome and prognosis of de novo CD5 positive diffuse large B cell lymphoma (CD5(+)DLBCL), clinical data of 10 patients with pathologically confirmed CD5(+)DLBCL were retrospectively analyzed. The results indicated that 9 out of 10 patients were older than 60 years. All cases were in III/IV stages according to Ann-Arbor Staging System. Bone marrow biopsy with immunohistochemistry showed lymphoma involvement in 5 cases. Nine patients received chemotherapy with anti-CD20 monoclonal antibody (Rituximab) except one. Five cases achieved CR, two cases achieved PR, two cases achieved SD, one case achieved PD. Eight cases died within 2 years because of relapse or disease progression, in which 3 cases developed central nervous system lymphoma. The median survival time was 16 (1-23) months, 2-year survival rate was 20.40%. It is concluded that de novo CD5(+) DLBCL is rare in clinic, but it is a kind of highly aggressive lymphoma with poor prognosis. So, new treatment strategy should be explored.
